EyePoint

EyePoint Revenue

The The revenue of EyePoint (EYPT) as of Oct 16, 2026 is 31.37 M USD. In the previous year, The revenue was 43.27 M USD — a change of -27.50% (lower).

Revenue

31.37 MUSD

YoY

-27.50%

Last updated:

In 2025, EyePoint's sales reached 31.37 M USD, a -27.50% difference from the 43.27 M USD sales recorded in the previous year.

Revenue has compounded at 17.5% per year over the past 19 years to 31.37 M USD.

The EyePoint Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2023
46.02 M USD
Jan 1, 2024
43.27 M USD
Jan 1, 2025
31.37 M USD
Jan 1, 2026 (e)
1.72 M USD
Jan 1, 2027 (e)
17.93 M USD
Jan 1, 2028 (e)
196.31 M USD
Jan 1, 2029 (e)
437.38 M USD
Jan 1, 2030 (e)
621.93 M USD
The EyePoint Revenue history
YEARRevenueYoY
est621.93 MUSD+42.19%
est437.38 MUSD+122.80%
est196.31 MUSD+995.14%
est17.93 MUSD+943.13%
est1.72 MUSD-94.52%
31.37 MUSD-27.50%
43.27 MUSD-5.97%
46.02 MUSD+11.14%
41.40 MUSD+12.09%
36.94 MUSD+7.27%
34.44 MUSD+69.10%
20.37 MUSD+587.77%
2.96 MUSD-60.72%
7.54 MUSD+365.37%
1.62 MUSD-93.90%
26.57 MUSD+664.90%
3.47 MUSD+62.06%
2.14 MUSD-39.22%
3.53 MUSD-28.98%
4.97 MUSD-78.46%
23.05 MUSD+89.55%
12.16 MUSD+249.88%
3.48 MUSD+55.53%
2.24 MUSD+52.52%
1.47 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EyePoint Revenue

EyePoint Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
46.02 M USD
-75.07 M USD
-70.80 M USD
Jan 1, 2024
43.27 M USD
-145.85 M USD
-130.87 M USD
Jan 1, 2025
31.37 M USD
-243.43 M USD
-231.96 M USD
Jan 1, 2026 (e)
1.72 M USD
-259.56 M USD
-209.36 M USD
Jan 1, 2027 (e)
17.93 M USD
-262.07 M USD
-153.54 M USD
Jan 1, 2028 (e)
196.31 M USD
-189.90 M USD
-91.82 M USD
Jan 1, 2029 (e)
437.38 M USD
10.50 M USD
6.12 M USD
Jan 1, 2030 (e)
621.93 M USD
121.31 M USD
73.40 M USD

EyePoint Margins

EyePoint stock margins

The EyePoint margin analysis displays the gross margin, EBIT margin, as well as the profit margin of EyePoint. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for EyePoint.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
89.93 %
-163.13 %
-153.84 %
Jan 1, 2024
91.42 %
-337.06 %
-302.43 %
Jan 1, 2025
93.41 %
-775.98 %
-739.42 %
Jan 1, 2026 (e)
93.41 %
-15,104.35 %
-12,182.78 %
Jan 1, 2027 (e)
93.41 %
-1,462.00 %
-856.53 %
Jan 1, 2028 (e)
93.41 %
-96.73 %
-46.77 %
Jan 1, 2029 (e)
93.41 %
2.40 %
1.40 %
Jan 1, 2030 (e)
93.41 %
19.51 %
11.80 %

EyePoint Stock analysis

What does EyePoint do? EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint is one of the most popular companies on Eulerpool.

Revenue Details

Understanding EyePoint's Sales Figures

The sales figures of EyePoint originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing EyePoint’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize EyePoint's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in EyePoint’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about EyePoint stock

The revenue of EyePoint is 31.37 M USD in 2025.

The revenue of EyePoint changed from 43.27 M USD to 31.37 M USD, representing a -27.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The revenue EyePoint since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's EyePoint historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — EyePoint

All Key Metrics — EyePoint